Blow For Novartis Eye Drug Beovu As Studies Stop On Safety Worries
Intraocular Inflammation Cases Higher Than Rival
Executive Summary
The Swiss giant Novartis has decided to halt the MERLIN, RAVEN and RAPTOR studies of Beovu "in the interests of patient safety" which will make the task of competing with the wet AMD market leader Eylea even tougher.
You may also be interested in...
Apellis’ Syfovre Sales Overshadowed By Safety Concerns
Second quarter sales of the new geographic atrophy drug exceeded expectations, but the company confirmed seven events of retinal vasculitis in patients treated with Syfovre in the real world.
Roche Has Eylea In Its Sights After Farcimab Approval
Roche’s bispecific antibody, to be called Vabysmo, has got US approval for wet age-related macular degeneration and diabetic macular edema, markets where Bayer and Regeneron's Eylea is a huge seller. The Swiss company hopes that its less-frequent dosing advantage and a price that offers savings over time will make an impact on the market.
Roche’s Port Delivery System Approved, Paving The Way For Ophthalmology Expansion
Susvimo, a PDS version of the blockbuster Lucentis, is a refillable eye implant that will extend Roche's commercial opportunity in wet-AMD but presents training challenges. Pricing is slightly below Lucentis.